Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 3,559 INR
Change Today +38.30 / 1.09%
Volume 407.7K
As of 7:05 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

dr. reddy's laboratories (DRRD) Snapshot

Open
3,497
Previous Close
3,521
Day High
3,565
Day Low
3,453
52 Week High
04/10/15 - 3,809
52 Week Low
06/30/14 - 2,555
Market Cap
606.6B
Average Volume 10 Days
315.0K
EPS TTM
130.22
Shares Outstanding
170.4M
EX-Date
07/10/15
P/E TM
27.3x
Dividend
20.00
Dividend Yield
0.51%
Current Stock Chart for DR. REDDY'S LABORATORIES (DRRD)

Related News

No related news articles were found.

dr. reddy's laboratories (DRRD) Related Businessweek News

No Related Businessweek News Found

dr. reddy's laboratories (DRRD) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to other companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the discovery, development, and commercialization of novel small molecule agents in therapeutic areas, such as anti-infective, metabolic disorders, and pain and inflammation. It also provides differentiated formulations for unmet medical needs; and a portfolio of in-licensed patented dermatology products As of March 31, 2015, this segment had 18 active products in proprietary products development pipeline that are in various stages of development. The company’s therapeutic categories primarily include gastro-intestinal, cardiovascular, pain management, oncology, dermatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; collaboration, license and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

20,373 Employees
Last Reported Date: 06/17/15
Founded in 1984

dr. reddy's laboratories (DRRD) Top Compensated Officers

Co-Chairman, Chief Executive Officer, Member ...
Total Annual Compensation: 6.3M
Chairman of The Board, Member of The Manageme...
Total Annual Compensation: 6.3M
Compensation as of Fiscal Year 2015.

dr. reddy's laboratories (DRRD) Key Developments

Dr. Reddy's Laboratories Wins GBP 200,128 Multiple Awardees Contract for Supplying Aripiprazole Medicines

Dr. Reddy's Laboratories, Cambridge, won a GBP 200,128 (excluding VAT) multiple awardees contract award from The Common Services Agency (more commonly known as NHS National Services Scotland) ('the Authority') for the supply of Aripiprazole medicines (Tablets) (Contract Award Notice No.: 2015/S 104-188988; Lot No.: 1).

Dr Reddy's Laboratories Limited Announces the Availability of Somazina

Dr Reddy's Laboratories Limited has announced the availability of Somazina, which is indicated for the management of stroke, in India. Somazina is the innovator brand of Citicoline. Dr. Reddy's has partnered with the global innovator of Citicoline, Ferrer Internacional S.A., Spain, to make Somazina available in India. This is an important product in the management of stroke and has been used for the treatment of post-stroke patients around the world. Citicoline is a widely used neuro-protectant to help accelerate the recovery of these patients. It is used in both ischemic and haemorrhagic strokes, and provides a compelling option to physicians treating stroke patients.

Dr Reddy's Laboratories Limited and Astrazeneca Pharma India Limited Enter Distribution Agreement

Dr. Reddy's Laboratories Ltd. and AstraZeneca Pharma India Limited entered into a distribution agreement for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination with metformin, in Type 2 Diabetes. Both Riax and Riax M are trademarks of the AstaZenca Group.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRD:IN 3,559.45 INR +38.30

DRRD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 1,452 INR +48.70
Cadila Healthcare Ltd 1,797 INR +81.00
Croda International PLC 2,781 GBp +4.00
Lonza Group AG SFr.126.10 CHF +1.30
Symrise AG €56.57 EUR +0.75
View Industry Companies
 

Industry Analysis

DRRD

Industry Average

Valuation DRRD Industry Range
Price/Earnings 26.8x
Price/Sales 4.0x
Price/Book 5.3x
Price/Cash Flow 26.7x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DR. REDDY'S LABORATORIES, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.